Evidence on the validity of drug targets from randomized trials is reliable but typically
expensive and slow to obtain. In contrast, evidence from conventional observational …

Longer human lives have led to a global burden of late-life disease. However, some older
people experience little ill health, a trait that should be extended to the general population …

This paper provides guidelines for performing Mendelian randomization investigations. It is
aimed at practitioners seeking to undertake analyses and write up their findings, and at …

Genome-wide association studies have yielded thousands of associations for many
common diseases and disease-related complex traits. The identified associations made it …

The human proteome is a major source of therapeutic targets. Recent genetic association
analyses of the plasma proteome enable systematic evaluation of the causal consequences …

Results from genome-wide association studies (GWAS) can be used to infer causal
relationships between phenotypes, using a strategy known as 2-sample Mendelian …

In this study, we leveraged the combined evidence of rare coding variants and common
alleles to identify therapeutic targets for osteoporosis. We undertook a large-scale …

Mendelian randomization (MR) is a burgeoning field that involves the use of genetic variants
to assess causal relationships between exposures and outcomes. MR studies can be …

Drugs whose targets have genetic evidence to support efficacy and safety are more likely to
be approved after clinical development. In this paper, we provide an overview of how natural …

Mendelian randomisation (MR) analysis is an important tool to elucidate the causal
relevance of environmental and biological risk factors for disease. However, causal …